Lousberg, T. R., Witt, D. M., Beall, D. G., Carter, B. L., and Malone, D. C. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch.Intern.Med. 3-9-1998;158(5):528-534. View abstract.
Lubetsky, A., Hoffman, R., Zimlichman, R., Eldor, A., Zvi, J., Kostenko, V., and Brenner, B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb.Res. 2004;113(6):371-378. View abstract.
Lubetsky, A., Yonath, H., Olchovsky, D., Loebstein, R., Halkin, H., and Ezra, D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch.Intern.Med. 11-10-2003;163(20):2469-2473. View abstract.
Maas, A. H., van der Schouw, Y. T., Beijerinck, D., Deurenberg, J. J., Mali, W. P., Grobbee, D. E., and van der Graaf, Y. Vitamin K intake and calcifications in breast arteries. Maturitas 3-20-2007;56(3):273-279. View abstract.
Macdonald, H. M., McGuigan, F. E., Lanham-New, S. A., Fraser, W. D., Ralston, S. H., and Reid, D. M. Vitamin K1 intake is associated with higher bone mineral density and reduced bone resorption in early postmenopausal Scottish women: no evidence of gene-nutrient interaction with apolipoprotein E polymorphisms. Am.J.Clin.Nutr. 2008;87(5):1513-1520. View abstract.
Makris, M., Greaves, M., Phillips, W. S., Kitchen, S., Rosendaal, F. R., and Preston, E. F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb.Haemost. 1997;77(3):477-480. View abstract.
Malik, S., Udani, R. H., Bichile, S. K., Agrawal, R. M., Bahrainwala, A. T., and Tilaye, S. Comparative study of oral versus injectable vitamin K in neonates. Indian Pediatr. 1992;29(7):857-859. View abstract.
Marti-Carvajal, A. J., Cortes-Jofre, M., and Marti-Pena, A. J. Vitamin K for upper gastrointestinal bleeding in patients with liver diseases. Cochrane.Database.Syst.Rev. 2008;(3):CD004792. View abstract.
Maurage, C., Dalloul, C., Moussa, F., Cara, B., Dudragne, D., Lion, N., and Amedee-Manesme, O. [Efficacy of oral administration of a micellaar solution of vitamin K during the neonatal period]. Arch.Pediatr. 1995;2(4):328-332. View abstract.
Morales, W. J., Angel, J. L., O'Brien, W. F., Knuppel, R. A., and Marsalisi, F. The use of antenatal vitamin K in the prevention of early neonatal intraventricular hemorrhage. Am.J.Obstet.Gynecol. 1988;159(3):774-779. View abstract.
Motohara, K., Endo, F., and Matsuda, I. Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet 8-3-1985;2(8449):242-244. View abstract.
Motohara, K., Endo, F., and Matsuda, I. Vitamin K deficiency in breast-fed infants at one month of age. J.Pediatr.Gastroenterol.Nutr. 1986;5(6):931-933. View abstract.
Patel, R. J., Witt, D. M., Saseen, J. J., Tillman, D. J., and Wilkinson, D. S. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20(10):1159-1166. View abstract.
Pathak A, Hamm CR, Eyal FG, Walter K, Rijhsinghani A, and Bohlman M. Maternal vitamin K administration for prevention of intraventricular hemorrhage in preterm infants. Pediatric Research 1990;27:219A.
Pendry, K., Bhavnani, M., and Shwe, K. The use of oral vitamin K for reversal of over-warfarinization. Br.J.Haematol. 2001;113(3):839-840. View abstract.
Pengo, V., Banzato, A., Garelli, E., Zasso, A., and Biasiolo, A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul.Fibrinolysis 1993;4(5):739-741. View abstract.
Penning-van Beest, F. J., Rosendaal, F. R., Grobbee, D. E., van, Meegen E., and Stricker, B. H. Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br.J.Haematol. 1999;104(2):241-245. View abstract.
Poli, D., Antonucci, E., Lombardi, A., Gensini, G. F., Abbate, R., and Prisco, D. Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation. Haematologica 2003;88(2):237-238. View abstract.
Pomerance, J. J., Teal, J. G., Gogolok, J. F., Brown, S., and Stewart, M. E. Maternally administered antenatal vitamin K1: effect on neonatal prothrombin activity, partial thromboplastin time, and intraventricular hemorrhage. Obstet.Gynecol. 1987;70(2):235-241. View abstract.
Preston, F. E., Laidlaw, S. T., Sampson, B., and Kitchen, S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br.J.Haematol. 2002;116(3):619-624. View abstract.
Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J.Hepatol. 1989;9(1):75-83. View abstract.
Puckett, R. M. and Offringa, M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. Cochrane.Database.Syst.Rev. 2000;(4):CD002776. View abstract.
Raj, G., Kumar, R., and McKinney, W. P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch.Intern.Med. 12-13-1999;159(22):2721-2724. View abstract.
Rashid, M., Durie, P., Andrew, M., Kalnins, D., Shin, J., Corey, M., Tullis, E., and Pencharz, P. B. Prevalence of vitamin K deficiency in cystic fibrosis. Am.J.Clin.Nutr. 1999;70(3):378-382. View abstract.
Rees, K., Guraewal, S., Wong, Y. L., Majanbu, D. L., Mavrodaris, A., Stranges, S., Kandala, N. B., Clarke, A., and Franco, O. H. Is vitamin K consumption associated with cardio-metabolic disorders? A systematic review. Maturitas 2010;67(2):121-128. View abstract.
Riegert-Johnson, D. L. and Volcheck, G. W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann.Allergy Asthma Immunol. 2002;89(4):400-406. View abstract.
Sasaki, N., Kusano, E., Takahashi, H., Ando, Y., Yano, K., Tsuda, E., and Asano, Y. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J.Bone Miner.Metab 2005;23(1):41-47. View abstract.
Sato, Y., Honda, Y., Hayashida, N., Iwamoto, J., Kanoko, T., and Satoh, K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. Arch.Phys.Med.Rehabil. 2005;86(3):576-581. [RETRACTED]. View abstract.
Sato, Y., Honda, Y., Kaji, M., Asoh, T., Hosokawa, K., Kondo, I., and Satoh, K. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31(1):114-118. [RETRACTED]. View abstract.
Sato, Y., Honda, Y., Kuno, H., and Oizumi, K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23(3):291-296. [RETRACTED]. View abstract.
Sato, Y., Kaji, M., Tsuru, T., Satoh, K., and Kondo, I. Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson's disease. Arch.Phys.Med.Rehabil. 2002;83(1):86-91. [RETRACTED]. View abstract.
Ameye, L. G. and Chee, W. S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006;8(4):R127. View abstract.
Baghdikian, B., Guiraud-Dauriac, H., Ollivier, E., N'Guyen, A., Dumenil, G., and Balansard, G. Formation of nitrogen-containing metabolites from the main iridoids of Harpagophytum procumbens and H. zeyheri by human intestinal bacteria. Planta Med 1999;65(2):164-166. View abstract.
Belaiche P. Etude clinique de 630 cas d'artrose traites par le nebulisat aqueux d'Harpagophytum procumbens (Radix). Phytotherapy 1982;1:22-28.
Betancor-Fernandez, A., Perez-Galvez, A., Sies, H., and Stahl, W. Screening pharmaceutical preparations containing extracts of turmeric rhizome, artichoke leaf, devil's claw root and garlic or salmon oil for antioxidant capacity. J Pharm Pharmacol 2003;55(7):981-986. View abstract.
Bhattacharya A and Bhattacharya SK. Anti-oxidative activity of Harpagophytum procumbens. Br J Phytother 1998;72:68-71.
Biller, A. Ergebnisse sweier randomisieter kontrollierter. Phyto-pharmaka 2002;7:86-88.
Boje, K., Lechtenberg, M., and Nahrstedt, A. New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase. Planta Med 2003;69(9):820-825. View abstract.
Brien, S., Lewith, G. T., and McGregor, G. Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med 2006;12(10):981-993. View abstract.
Chrubasik S and Eisenberg E. Treatment of rheumatic pain with Kampo medicine in Europe. The Pain Clinic 1999;11(3):171.
Chrubasik S, Fiebich B, Black A, and et al. Treating low back pain with an extract of Harpagophytum procumbens that inhibits cytokine release. Eur J Anaesthesiol 2002;19:209.
Chrubasik S, Schmidt A, Junck H, and et al. [Effectiveness and economy of Harpagophytum extract in the treatment of acute low back pain - first results of a therapeutic cohort study]. Forsch Komplementarmed 1997;4:332-336.
Chrubasik S, Sporer F, and Wink M. [Content of active substance in tea preparations from Harpagophytum procumbens]. Forsch Komplementarmed 1996;3:116-119.
Chrubasik S, Sporer F, and Wink M. [Harpagoside content of different powdered dry extracts from Harpagophytum procumbens]. Forsch Komplmentarmed 1996;3:6-11.
Chrubasik S, Sporer F, Wink M, and et al. Zum wirkstoffgehalt in arzneimitteln aus harpagophytum procumbens. Forsch Komplementärmed 1996;3:57-63.
Chrubasik S, Zimpfer C, Schutt U, and et al. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine 1996;3(1):1-10.
Chrubasik, S. [Devil's claw extract as an example of the effectiveness of herbal analgesics]. Orthopade 2004;33(7):804-808. View abstract.
Chrubasik, S. Addendum to the ESCOP monograph on Harpagophytum procumbens. Phytomedicine. 2004;11(7-8):691-695. View abstract.
Chrubasik, S., Conradt, C., and Roufogalis, B. D. Effectiveness of Harpagophytum extracts and clinical efficacy. Phytother.Res. 2004;18(2):187-189. View abstract.
Chrubasik, S., Junck, H., Breitschwerdt, H., Conradt, C., and Zappe, H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double- blind study. Eur.J Anaesthesiol. 1999;16(2):118-129. View abstract.
Clarkson, C., Campbell, W. E., and Smith, P. In vitro antiplasmodial activity of abietane and totarane diterpenes isolated from Harpagophytum procumbens (devil's claw). Planta Med 2003;69(8):720-724. View abstract.
Eichler, O. and Koch, C. [Antiphlogistic, analgesic and spasmolytic effect of harpagoside, a glycoside from the root of Harpagophytum procumbens DC]. Arzneimittelforschung. 1970;20(1):107-109. View abstract.
Erdos, A., Fontaine, R., Friehe, H., Durand, R., and Poppinghaus, T. [Contribution to the pharmacology and toxicology of different extracts as well as the harpagosid from Harpagophytum procumbens DC]. Planta Med 1978;34(1):97-108. View abstract.
Ernst, E. and Chrubasik, S. Phyto-anti-inflammatories. A systematic review of randomized, placebo-controlled, double-blind trials. Rheum.Dis Clin North Am 2000;26(1):13-27, vii. View abstract.
Ficarra P, Ficarra R, Tommasini A, and et al. [HPLC analysis of a drug in traditional medicine: Harpagophytum procumbens DC. I]. Boll Chim Farm 1986;125(7):250-253.
Fontaine, J., Elchami, A. A., Vanhaelen, M., and Vanhaelen-Fastre, R. [Biological analysis of Harpagophytum procumbens D.C. II. Pharmacological analysis of the effects of harpagoside, harpagide and harpagogenine on the isolated guinea-pig ileum (author's transl)]. J Pharm Belg. 1981;36(5):321-324. View abstract.
Frerick H, Biller A, and Schmidt U. Stufenschema bei Coxarthrose. Der Kassenarzt 2001;5(34):41.
Gagnier, J. J., van Tulder, M., Berman, B., and Bombardier, C. Herbal medicine for low back pain. Cochrane.Database.Syst.Rev. 2006;(2):CD004504. View abstract.
Gobel, H., Heinze, A., Ingwersen, M., Niederberger, U., and Gerber, D. [Effects of Harpagophytum procumbens LI 174 (devil's claw) on sensory, motor und vascular muscle reagibility in the treatment of unspecific back pain]. Schmerz. 2001;15(1):10-18. View abstract.
Grant, L., McBean, D. E., Fyfe, L., and Warnock, A. M. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res 2007;21(3):199-209. View abstract.
Guyader M. Les plantes antirhumatismales. Etude historique et pharmacologique, et etude clinique du nebulisat d'Harpagohytum procumbens DC chez 50 patients arthrosiques suivis en service hospitalier [Dissertation]. Universite Pierre et Marie Curie, 1984.
Jadot G and Lecomte A. Activite anti-inflammatoire d'Harpagophytum procumbens DC. Lyon Mediteranee Med Sud-Est 1992;28:833-835.
Kaszkin, M., Beck, K. F., Koch, E., Erdelmeier, C., Kusch, S., Pfeilschifter, J., and Loew, D. Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagoside-dependent and independent effects. Phytomedicine. 2004;11(7-8):585-595. View abstract.
Kikuchi T. New iridoid glucosides from Harpagophytum procumbens. Chem Pharm Bull 1983;31:2296-2301.
Kundu, J. K., Mossanda, K. S., Na, H. K., and Surh, Y. J. Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. Cancer Lett. 1-31-2005;218(1):21-31. View abstract.
Langmead L, Dawson C, Hawkins C, and et al. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 2002;16(2):197-205.
Laudahn, D. and Walper, A. Efficacy and tolerance of Harpagophytum extract LI 174 in patients with chronic non-radicular back pain. Phytother.Res. 2001;15(7):621-624. View abstract.
Leblan, D., Chantre, P., and Fournie, B. Harpagophytum procumbens in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein. Joint Bone Spine 2000;67(5):462-467. View abstract.
Lecomte A and Costa JP. Harpagophytum dans l'arthrose: Etude en double insu contre placebo. Le Magazine 1992;15:27-30.
Loew D, Schuster O, and Möllerfeld J. Stabilität und biopharmazeutische Qualität. Voraussetzung für Bioverfügbarkeit von Harpagophytum procumbens. In: Loew D and Rietbrock N. Phytopharmaka II. Forschung und klinische Anwendung. Darmstadt: Forschung und klinische Anwendung;1996.
Loew, D., Mollerfeld, J., Schrodter, A., Puttkammer, S., and Kaszkin, M. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin.Pharmacol.Ther. 2001;69(5):356-364. View abstract.
Munkombwe, N. M. Acetylated phenolic glycosides from Harpagophytum procumbens. Phytochemistry 2003;62(8):1231-1234. View abstract.
Na, H. K., Mossanda, K. S., Lee, J. Y., and Surh, Y. J. Inhibition of phorbol ester-induced COX-2 expression by some edible African plants. Biofactors 2004;21(1-4):149-153. View abstract.
Occhiuto, F., Circosta, C., Ragusa, S., Ficarra, P., and Costa, De Pasquale. A drug used in traditional medicine: Harpagophytum procumbens DC. IV. Effects on some isolated muscle preparations. J Ethnopharmacol. 1985;13(2):201-208. View abstract.
Pinget M and Lecompte A. Etude des effets de I'harpagophytum en rhumatologie dégénérative. 37 Le magazine 1990;(10):1-10.
Pinget, M. and Lecomte, A. The effect of Harpagophytum Arkocaps in degenerative rheumatism [in German]. Naturheilpraxis 1997;50:267-269.
Ribbat JM and Schakau D. Behandluing chronisch aktivierter Schmerzen am Bewegungsapparat. NaturaMed 2001;16:23-30.
Rutten, S. and Schafer, I. Einsatz der afrikanischen Teufelskralle [Allya] bei Erkrankungen des Stutz unde Bewegungsapparates. Ergebnisse einer Anwendungscbeobachtung Acta Biol 2000;2:5-20.
Schendel, U. Arthritis treatment: Study with Devil Claw extract [in German]. Der Kassenarzt 2001;29/30:2-5.
Schmelz H, Haemmerle HD, and Springorum HW. Analgetische Wirksamkeit eines Teufels-krallenwurzel-Extraktes bei verschiedenen chronisch-degenerativen Gelenkerkrankungen. In: Chrubasik S and Wink M. Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates;1997.
Schrüffer H. Salus Teufelskralle-Tabletten. Ein Fortschritt in der nichtsteroidalen antirheumatischen Therapie. Die Medizinische Publikation 1980;1:1-8.
Schulze-Tanzil, G., Hansen, C., and Shakibaei, M. [Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro]. Arzneimittelforschung. 2004;54(4):213-220. View abstract.
Spelman, K., Burns, J., Nichols, D., Winters, N., Ottersberg, S., and Tenborg, M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern.Med.Rev. 2006;11(2):128-150. View abstract.
Teut, M. and Warning, A. [Bone metastases in breast carcinoma]. Forsch Komplement.Med (2006.) 2006;13(1):46-48. View abstract.
Tunmann P and Bauersfeld HJ. Über weitere Inhaltsstoffe der Wurzel von Harpagophytum procumbens DC. Arch Pharm (Weinheim) 1975;308(8):655-657.
Tunmann P and Lux R. Zur Kenntnis der Inhaltsstoffe aus der Wurzel von Harpagophytum procumbens DC. DAZ 1962;102(40):1274-1275.
Usbeck, C. Teufelskralle: Devil claw: Treatment for chronic pain [in German]. Arzneimittel-Forum 2000;3:23-25.
Anon. Devil's claw root: ulcers and gastrointestinal bleeding. Prescrire Int 2013;22(144):296. View abstract.
Baghdikian B, Lanhers MC, Fleurentin J, et al. An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Planta Med 1997;63:171-6. View abstract.
Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. Alcohol 1996;13:395-8. View abstract.
Carvalho RR, Donadel CD, Cortez AF, Valviesse VR, Vianna PF, Correa BB. J Bras Nefrol. 2017 Mar;39(1):79-81. View abstract.
Chantre P, Cappelaere A, Leblan D, et al. Efficacy and tolerance or Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000;7:177-83. View abstract.
Chrubasik S, Kunzel O, Thanner J, et al. A 1-year follow-up after a pilot study with Doloteffin for low back pain. Phytomedicine 2005;12:1-9. View abstract.
Chrubasik S, Model A, Black A, and et al. A randomized double-blind pilot study comparing Doloteffin® and Vioxx® in the treatment of low back pain. Rheumatology 2003;42:141-148.
Chrubasik S, Sporer F, Dillmann-Marschner R, et al. Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets. Phytomedicine 2000;6:469-73. View abstract.
Chrubasik S, Thanner J, Kunzel O, et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002;9:181-94. View abstract.
Circosta C, Occhiuto F, Ragusa S, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. II. Cardiovascular activity. J Ethnopharmacol 1984;11:259-74. View abstract.
Conrozier T, Mathieu P, Bonjean M, et al. A complex of three natural anti-inflammatory agents provides relief of osteoarthritis pain. Altern Ther Health Med. 2014;20 Suppl 1:32-7.View abstract.
Costa De Pasquale R, Busa G, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. III. Effects on hyperkinetic ventricular arrhythmias by reperfusion. J Ethnopharmacol 1985;13:193-9 . View abstract.
Cuspidi C, Sala C, Tadic M, et al. Systemic hypertension induced by Harpagophytum procumbens (devil's claw): a case report. J Clin Hypertens (Greenwich) 2015;17(11):908-10. View abstract.
Diaz-Silveira GL, Deutsch J, Little DP. DNA Barcode Authentication of Devil's Claw Herbal Dietary Supplements. Plants (Basel) 2021;10(10):2005. View abstract.
Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine 2001;8:28-30.. View abstract.
Gagnier JJ, Chrubasik S, Manheimer E. Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004;4:13. View abstract.
Gagnier JJ, van Tulder MW, Berman B, Bombardier C. Herbal medicine for low back pain. A Cochrane review. Spine 2007;32:82-92. View abstract.
Grahame R, Robinson BV. Devils's claw (Harpagophytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 1981;40:632. View abstract.
Hagiwara H, Seki T, Ariga T. The effect of pre-germinated brown rice intake on blood glucose and PAI-1 levels in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 2004;68:444-7. View abstract.
Jang MH, Lim S, Han SM, et al. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci 2003;93:367-71. View abstract.
Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-4. View abstract.
Lanhers MC, Fleurentin J, Mortier F, et al. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 1992;58:117-23 . View abstract.
Mahomed IM, Ojewole JAO. Oxytocin-like effect of Harpagophytum procumbens [Pedaliacae] secondary root aqueous extract on rat isolated uterus. Afr J Trad CAM 2006;3(1):82-89.
More M, Gruenwald J, Pohl U, Uebelhack R. A Rosa canina - Urtica dioica - Harpagophytum procumbens/zeyheri combination significantly reduces gonarthritis symptoms in a randomized, placebo-controlled double-blind study. Planta Med. 2017 Dec;83(18):1384-91. View abstract.
Moussard C, Alber D, Toubin MM, et al. A drug used in traditional medicine, harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids. 1992;46:283-6.. View abstract.
Romiti N, Tramonti G, Corti A, Chieli E. Effects of Devil's Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein. Phytomedicine 2009;16:1095-100. View abstract.
Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997;17:342-56. View abstract.
Soulimani R, Younos C, Mortier F, Derrieu C. The role of stomachal digestion on the pharmacological activity of plant extracts, using as an example extracts of Harpagophytum procumbens. Can J Physiol Pharmacol 1994;72:1532-6. View abstract.
Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.
Vu N, Nguyen TTT, Parmenter BH, Thouas GA. Safety, efficacy and tolerability of a combination micronutrient and polyherbal preparation (GoutFighter TM) for gout: a single-arm open-label pilot study. J Complement Integr Med 2020;18(1):113-21. View abstract.
Wegener T, Lupke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC). Phytother Res 2003;17:1165-72. View abstract.
Whitehouse LW, Znamirowska M, Paul CJ. Devil's Claw (Harpagophytum procumbens): no evidence for anti-inflammatory activity in the treatment of arthritic disease. Can Med Assoc J 1983;129:249-51. View abstract.
Zegota Z, Gozdzik J, Glogowska-Szelag J. Prospective, multicenter evaluation of a polyherbal supplement alongside standard-of-care treatment for mild knee osteoarthritis. Adv Orthop. 2021;2021:5589597. View abstract.
You Might Also Like
Select a condition to view a list of vitamins
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.